Why is BIOTON SA ?
- The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
- Poor long term growth as Net Sales has grown by an annual rate of 9.87% and Operating profit at 52.69% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 0.57 times
- The company has been able to generate a Return on Equity (avg) of 1.05% signifying low profitability per unit of shareholders funds
- The company has declared positive results in Jan 70 after 4 consecutive negative quarters
- NET SALES(HY) At PLN 152.51 MM has Grown at 64.71%
- DEBT-EQUITY RATIO (HY) Lowest at 7.05 %
- INTEREST COVERAGE RATIO(Q) The company hardly has any interest cost
How much should you hold?
- Overall Portfolio exposure to BIOTON SA should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is BIOTON SA for you?
Low Risk, Medium Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
At PLN 152.51 MM has Grown at 64.71%
Lowest at 7.05 %
The company hardly has any interest cost
Fallen by -4.92% (YoY
Highest at 1.99 times
Highest at 8.84 times
Highest at PLN 17.64 MM
Highest at 24.28 %
Highest at PLN 6.28 MM
Highest at PLN 4.35 MM
Highest at PLN 0.05
Lowest at PLN 3.02 MM
Here's what is working for BIOTON SA
Pre-Tax Profit (PLN MM)
Net Profit (PLN MM)
Net Sales (PLN MM)
Debt-Equity Ratio
Operating Profit (PLN MM)
Operating Profit to Sales
Pre-Tax Profit (PLN MM)
Net Profit (PLN MM)
EPS (PLN)
Inventory Turnover Ratio
Debtors Turnover Ratio
Raw Material Cost as a percentage of Sales
Here's what is not working for BIOTON SA
Cash and Cash Equivalents






